Antiplatelet therapy as means of secondary prevention of ischemic stroke
Abstract
Ischemic stroke (AI) is a common disabling disease, the effectiveness of prevention of which largely depends on the correctly chosen pathogenetic therapy. Acetylsalicylic acid (ASA) has been used for the prevention of AI for many years, but the results of its use are often limited by its low sensitivity. Modern data on the effectiveness of dipyridamole (Curantyl) as a means of secondary prevention of AI, in particular, in conditions combined with ASA therapy, are considered. It is noted that there is reason to expect the most significant result when it is used in patients with atherothrombotic and lacunar AI. Possible complications of treatment are analyzed.
About the Authors
P. R. Kamchatnov
Russian National Research Medical University n.a. N. I. Pirogov
Russian Federation
Russian Federation
B. A. Abusueva
Dagestan State Medical University
Russian Federation
Russian Federation
E. N. Ismailzadeh
Dagestan State Medical University
Russian Federation
Russian Federation
K. B. Manysheva
Dagestan State Medical University
Russian Federation
Russian Federation
References
1. Гусев Е. И., Скворцова В. И., Стаховская Л. В. Эпидемиология инсульта в России. Журнал неврологии и психиатрии им. С. С. Корсакова. Инсульт. 2003; 8: 4-9.
2. Mozaffarian D., Benjamin J., Go A. et al. Heart Disease and Stroke Statistics - 2015 Update. A Report From the American Heart Association. Circulation. 2015; 131: e1-e293.
3. Hartley A., Marshall D., Salciccioli J. et al. Trends in Mortality from Ischaemic Heart Disease and Cerebrovascular Disease in Europe: 1980-2009. Circulation. 2016; 133 (20): 1916-26. doi: 10.1161/CIRCULATIONAHA.115.018931.
4. Vangen-L0nne A., Wilsgaard T., Johnsen S. Declining Incidence of Ischemic Stroke. What Is the Impact of Changing Risk Factors? The Troms0 Study 1995 to2012. Stroke. 2017; 48 (3): 544-550. doi: 10.1161/STROKEAHA. 116.014377.
5. Antithrombotic Trialists’ (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009; 373 (9678): 1849-1860.
6. Berrouschot J., Schwetlck B., von Twickel G. et al. Aspirin resistance in secondary stroke prevention. Acta Neurol. Scand. 2006; 113 (1): 31-35.
7. Michelson A., Cattaneo M., Eikelboom J. еt al. Aspirin Resistance: Position Paper of the Working Group on Aspirin Resistance, Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. J. Thromb. Haemost. 2005; 3: 1-3.
8. Diener H., Cunha L., Forbes C. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J. Nerol. Sci. 1996; 143:5-13.
9. Forbes C. Secondary stroke prevention with low-dose aspirin, sustained release dipyridamole alone and in combination. ESPS Investigators. European Stroke Prevention Study. Thromb. Res. 1998; 92 (1 Suppl. 1): S 1-6.
10. Hervey P., Goa K. Extended-release dipyridamole/aspirin. Drugs. 1999; 58 (3): 469-475.
11. Scheen A. Pharma-clinics. The drug of the month. Dipyridamole-acetylsalicylic acid combination (Aggrenox). Rev. Med. Liege. 2000; 55 (10): 957-959.
12. Sacco R., Diener H.-C., Yusuf S. et al. Aspirin andExtended-Release Dipyridamole versus Clopidogrel for Recurrent Stroke. N. Engl. J. Med. 2008; 359: 67-74.
13. De Schryver E., Algra A., van Gijn J. Dipyridamole for preventing stroke and other vascular events in patients with vascular disease. Cochrane Database Syst. Rev. 2006; (2): CD 001820.
14. Halkes P., van Gijn J., Kappelle L. et al. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet. 2006; 367 (9523): 1665-73. doi: 10.1016/S 0140-6736(06)68734-5.
15. Kwok C., Shoamanesh A., Copley H. et al. Efficacy of Antiplatelet Therapy in Secondary Prevention Following Lacunar Stroke. Pooled Analysis of Randomized Trials. Stroke. 2015; 46: 1014-1023. DOI: 10.1161/ STROKEAHA.114.008422.
16. Williams B., Poulter N. R., Brown M. J., Davis M., McInnes G. T., Potter J. F.; the BHS guide lines working party, for the British Hypertension Society. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV). BMJ 2004; 328: 634-40.
17. Felmeden D., Lip G. Antithrombotic therapy in hypertension: a Cochrane Systematic review. Journal of Human Hypertension. 2005; 19: 185-196.
18. Bautista L., Lina V. Antihypertensive Effects of Aspirin: What is the Evidence? Cur. Hypert. Rep. 2010. 10.1007/s11906-010-0115-5.
19. Shantsila E., Lip G. Y. Antiplatelet versus anticoagulation treatment for patients with heart failure in sinus rhythm. Cochrane Database Syst. Rev. 2016 Sep 15; 9: CD 003333.
20. Niu P.-P., Guo Z.-N., Jin H., et al. Antiplatelet regimens in the long-term secondary prevention of transient ischaemic attack and ischaemic stroke: an updated network metaanalysis. BMJ Open 2016; 6: e009013. doi: 10.1136/bmjopen-2015-009013.
21. Dengler R., Diener C., Schwartz A. et al. Early treatment with aspirin plus extended-release dipyridamole for transient ischaemic attack or ischaemic stroke within 24 h of symptom onset (EARLY trial): a randomised, open-label, blinde-dendpoint trial. Lancet Neurol. 2010; 9: 159-166.
22. Rothwell P., Algra A., Chen 1. et al. Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: time-course analysis of randomised trials. The Lancet. 2016; 388: 365-375. DOI: http://dx. doi.org. 10.1016/S 0140-6736(16)30468-8.
23. Furie K., Kasner S., Adams R. et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack. A guideline for healthcare professionals from the American Heart Association / American Stroke Association. Stroke. 2011; 42:227-276.
24. European Stroke Organisation (ESO) Executive Committee; ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack2008. Cerebrovasc. Dis. 2008; 25: 457-507.
25. Balakumar P., Varatharajan R., Nyo YH. et al. Fenofibrate and dipyridamole treatments in low-doses either alone or in combination blunted the development of nephropathy in diabetic rats. Pharmacol Res. 2014; 90: 36-47. doi: 10.1016/j.phrs.2014.08.008.
26. Hung CC., Yang ML., Lin MY. et al. Dipyridamole treatment is associated with improved renal outcome and patient survival in advanced chronic kidney disease. Kaohsi-ung J Med Sci. 2014; 30 (12): 599-607. doi: 10.1016/j.kjms.2014.10.002.
27. Hong K.-S. Dual Antiplatelet Therapy after Noncardioembolic Ischemic Stroke or Transient Ischemic Attack: Pros and Cons. J. Clin. Neurol. 2014; 10 (3): 189-196. doi. org/10.3988/jcn.2014.10.3.189.
28. de Vos-Koppelaar N., Kerkhoff H., de Vogel E. et al. The effect of a slower than standard dose escalation scheme for dipyridamole on headaches in secondary prevention therapy of strokes: a randomized, open-label trial (DOSE). Cerebrovasc. Dis. 2014; 37 (4): 285-9. doi: 10.1159/000360751.
29. Davidai G., Cotton D., Gorelick P. et al. Dipyridamole-induced headache and lower recurrence risk in secondary prevention of ischaemic stroke: a post hoc analysis. Eur. J. Neurol 2014; 21 (10): 1311-7. doi: 10.1111/ene.12484.
Review
For citations:
Kamchatnov P.R., Abusueva B.A., Ismailzadeh E.N., Manysheva K.B. Antiplatelet therapy as means of secondary prevention of ischemic stroke. Medical alphabet. 2017;2(15):57-62. (In Russ.)
Views:
276
Email this article 